<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Auranofin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Auranofin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Auranofin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8999" href="/d/html/8999.html" rel="external">see "Auranofin: Drug information"</a> and <a class="drug drug_patient" data-topicid="12009" href="/d/html/12009.html" rel="external">see "Auranofin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708624"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Gold toxicities:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Auranofin contains gold and, like other gold-containing drugs, can cause gold toxicity, signs of which include: Fall in hemoglobin, leukopenia &lt;4,000 WBC/mm<sup>3</sup>, granulocytes &lt;1,500/mm<sup>3</sup>, decrease in platelets &lt;150,000/mm<sup>3</sup>, proteinuria, hematuria, pruritus, rash, stomatitis or persistent diarrhea.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate use:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Like other gold preparations, auranofin is only indicated for use in selected patients with active rheumatoid arthritis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Physicians planning to use auranofin should be experienced with chrysotherapy and should thoroughly familiarize themselves with the toxicity and benefits of auranofin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Monitoring:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The results of recommended laboratory work should be reviewed before writing each auranofin prescription. In addition, the following precautions should be routinely employed: The possibility of adverse reactions should be explained to patients before starting therapy and patients should be advised to report promptly any symptoms suggesting toxicity.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F138065"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ridaura</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866012"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ridaura</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056705"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gold Compound</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812481"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis: </b>Limited data available: <b>Note:</b> Due to lack of favorable prospective data, auranofin is no longer recommended as a preferred choice for treatment of juvenile idiopathic arthritis and no longer appears as a treatment option in the US guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35233993','lexi-content-ref-16204667']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35233993','lexi-content-ref-16204667'])">Ref</a></span>). Reserve for patients intolerant to or unresponsive to other therapies.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥18 months and Adolescents ≤17 years: Oral: Initial: 0.1 to 0.15 mg/kg/day in 1 to 2 divided doses; usual maintenance: 0.15 mg/kg/day in 1 to 2 divided doses; maximum daily dose: 0.2 mg/kg/<b>day</b> or 9 mg/<b>day</b>. <b>Note:</b> With current market availability, may not be able to replicate the exact dosing used in trials; in trials, doses were rounded to nearest whole mg using 1 mg tablet (no longer available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6419599','lexi-content-ref-2183804','lexi-content-ref-1941832','lexi-content-ref-3044374']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6419599','lexi-content-ref-2183804','lexi-content-ref-1941832','lexi-content-ref-3044374'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729596"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F52729597"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; may increase risk of and/or symptoms of gold toxicity.</p></div>
<div class="block doa drugH1Div" id="F138068"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8999" href="/d/html/8999.html" rel="external">see "Auranofin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32775de1-c27b-4d28-84e6-04adfdee9a40">Rheumatoid arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Rheumatoid arthritis:</b> Oral: Initial: 6 mg/day in 1 or 2 divided doses; after 6 months may be increased to 9 mg/day in 3 divided doses; discontinue therapy if no response after 3 months at 9 mg/day</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Signs of clinical improvement may not be evident until after 3 months of therapy.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990395"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. The following guidelines have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:2em;">GFR 51 to 80 mL/minute: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:2em;">GFR ≤50 mL/minute: Avoid use.</p></div>
<div class="block doha drugH1Div" id="F50987549"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F138038"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin rash (24%), pruritus (17%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Diarrhea (≤47%), loose stools (≤47%), abdominal pain (14%), stomatitis (13%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Alopecia (1% to 3%), urticaria (1% to 3%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Nausea (10%), vomiting (10%), anorexia (3% to 9%), dyspepsia (3% to 9%), flatulence (3% to 9%), constipation (1% to 3%), dysgeusia (1% to 3%), glossitis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Genitourinary: Proteinuria (3% to 9%), hematuria (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hematologic and Oncologic: Anemia (1% to 3%), eosinophilia (1% to 3%), leukopenia (1% to 3%), thrombocytopenia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hepatic: Increased serum transaminases (1% to 3%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ophthalmic: Conjunctivitis (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, aplastic anemia, angioedema, bronchitis (gold), corneal deposits, dysphagia, exfoliative dermatitis (other gold compounds), fever, gastrointestinal hemorrhage, gingivitis, hepatotoxicity, interstitial pneumonitis, jaundice, metallic taste, melena, neutropenia, pancytopenia, peripheral neuropathy, pure red cell aplasia, ulcerative enterocolitis</p></div>
<div class="block coi drugH1Div" id="F138052"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of gold-induced disorders, including anaphylactic reactions, bone marrow aplasia, severe hematologic disorders, exfoliative dermatitis, necrotizing enterocolitis, or pulmonary fibrosis.</p></div>
<div class="block war drugH1Div" id="F138035"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: <b>[US Boxed Warning]: Signs of gold toxicity include pruritus, rash, and stomatitis. </b>Stomatitis and dermatitis are common reactions and may be serious (including exfoliative dermatitis). Pruritus and metallic taste may occur before dermatitis and oral mucous membrane reactions, respectively, and should be considered warning signs. Stomatitis may be manifested by shallow ulcers on the buccal membranes, on border of tongue, and on palate or in the pharynx; sometimes diffuse glossitis or gingivitis develops. Gold dermatitis may be aggravated by sunlight exposure, or an actinic rash may develop. Use with caution in patients with skin rash; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: <b>[US Boxed Warning]: Signs of gold toxicity include persistent diarrhea/loose stools,</b> as well as nausea, vomiting, anorexia, abdominal cramps, and ulcerative enterocolitis (rare). Diarrhea may be managed with a dose reduction. Use with caution in patients with inflammatory bowel disease; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect. In pediatric trials evaluating off-label use, diarrhea was the most common adverse effect (Giannini 1990). Monitor patients for GI bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: <b>[US Boxed Warning]: Signs of gold toxicity include hematologic depression (decreased hemoglobin, leukocytes (WBC &lt;4000/mm<sup>3</sup>), granulocytes (&lt;1500/mm<sup>3</sup>), or decreased platelets (&lt;150,000/mm<sup>3</sup>).</b> Use with caution in patients with bone marrow depression; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect. Therapy should be discontinued if signs and symptoms (eg, purpura, ecchymoses, petechiae) of thrombocytopenia develop or if platelet count falls to &lt;100,000/mm<sup>3</sup>; therapy should not be reinitiated until thrombocytopenia resolves and if thrombocytopenia was not caused by the gold therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: May be associated with the development of cholestatic jaundice (rare). Use with caution in patients with hepatic impairment; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: May be associated with rare reactions, including gold bronchitis, interstitial pneumonitis and fibrosis; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: <b>[US Boxed Warning]: Signs of gold toxicity include proteinuria and hematuria.</b> Renal toxicity ranges from mild proteinuria to nephrotic syndrome or glomerulitis with proteinuria and hematuria. Use with caution in patients with renal impairment; may increase risk and/or symptoms of gold toxicity and toxicity may be more difficult to detect. Therapy should be discontinued promptly if proteinuria or microscopic hematuria develops.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[US Boxed Warning]: Use is only indicated in select patients with active rheumatoid arthritis.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: <b>[US Boxed Warning]: Physicians should be experienced with chrysotherapy and should be familiar with the toxicity and benefits of therapy.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Monitoring: <b>[US Boxed Warning]: Laboratory monitoring should be reviewed prior to each new prescription. The possibility of adverse reactions should be discussed with patients prior to starting therapy and patients should be advised to promptly report any symptoms suggesting toxicity.</b> Disease states should be stable prior to initiating therapy.</p></div>
<div class="block foc drugH1Div" id="F138047"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ridaura: 3 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow)]</p></div>
<div class="block geq drugH1Div" id="F138031"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F138054"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ridaura Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $31.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866013"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ridaura: 3 mg</p></div>
<div class="block admp drugH1Div" id="F52612277"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Take with or without food; some centers have recommended to administer with food if it causes GI upset.</p></div>
<div class="block sts drugH1Div" id="F2555311"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53565561"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of active stage of classic or definite rheumatoid arthritis in patients who do not respond to or tolerate other agents (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F138109"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ridaura may be confused with Cardura</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298799"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218148"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13273270"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53565560"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline and periodic (at least monthly): CBC with differential, platelet count, urinalysis for protein; baseline renal and liver function tests; skin and oral mucosa examinations; specific questioning for symptoms of pruritus, rash, stomatitis, or metallic taste.</p></div>
<div class="block pha drugH1Div" id="F138034"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The exact mechanism of action of gold is unknown; gold salts decrease cellular proliferation, reduce antibody and cytokine release, and inhibit collagenase action (Doan 2005).</p></div>
<div class="block phk drugH1Div" id="F138051"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to rapid metabolism, the pharmacokinetics of auranofin are based on gold concentrations, not auranofin.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Delayed; therapeutic response may not be seen for 3-4 months after start of therapy, as long as 6 months in some patients</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Prolonged</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: ~25% gold in dose is absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 60%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapid; intact auranofin not detectable in the blood</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination (single or multiple dose dependent): 21 to 31 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~2 hours (Blocka 1986)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~60% of absorbed gold); remainder in feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038534"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ridaura</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ridaura</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ridaura</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 170.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3082559">
<a name="3082559"></a>Blocka KL, Paulus HE, Furst DE. Clinical pharmacokinetics of oral and injectable gold compounds. <i>Clin Pharmacokinet</i>. 1986;11(2):133-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/3082559/pubmed" id="3082559" target="_blank">3082559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6419599">
<a name="6419599"></a>Brewer EJ, Giannini EH, Person DA. Early experiences with auranofin in juvenile rheumatoid arthritis. <i>Am J Med</i>. 1983;75(6A):152-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/6419599/pubmed" id="6419599" target="_blank">6419599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15951465">
<a name="15951465"></a>Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. <i>J Clin Pharmaco</i>l. 2005;45(7):751-762. doi: 10.1177/0091270005277938.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/15951465/pubmed" id="15951465" target="_blank">15951465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1941832">
<a name="1941832"></a>Giannini EH, Barron KS, Spencer CH, et al. Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial. <i>J Rheumatol</i>. 1991;18(8):1240-1242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/1941832/pubmed" id="1941832" target="_blank">1941832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2183804">
<a name="2183804"></a>Giannini EH, Brewer EJ, Kuzmina N, et.al. Auranofin in the treatment of juvenile rheumatoid arthritis. <i>Arthritis Rheum</i>. 1990;33(4):466-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/2183804/pubmed" id="2183804" target="_blank">2183804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16204667">
<a name="16204667"></a>Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. <i>JAMA</i>. 2005;294(13):1671-1684. doi:10.1001/jama.294.13.1671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/16204667/pubmed" id="16204667" target="_blank">16204667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3044374">
<a name="3044374"></a>Marcolongo R, Mathieu A, Pala R, Giordano N, Fioravanti A, Panzarasa R. The efficacy and safety of auranofin in the treatment of juvenile rheumatoid arthritis. A long-term open study. <i>Arthritis Rheum</i>. 1988;31(8):981-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/3044374/pubmed" id="3044374" target="_blank">3044374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35233993">
<a name="35233993"></a>Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. <i>Arthritis Rheumatol</i>. 2022;74(4):553-569. doi:10.1002/art.42037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/auranofin-pediatric-drug-information/abstract-text/35233993/pubmed" id="35233993" target="_blank">35233993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sebela.1">
<a name="Sebela.1"></a>Ridaura (auranofin) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; October 2017.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12895 Version 132.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
